Remedent, Inc. (REMI)
USD 0.03
(-17.14%)
USD 0.03
(-17.14%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 986.22 Thousand USD | 14.17% |
| 2023 | 863.81 Thousand USD | -38.63% |
| 2022 | 1.4 Million USD | 36.68% |
| 2021 | 1.02 Million USD | -3.24% |
| 2020 | 1.06 Million USD | -33.63% |
| 2019 | 1.6 Million USD | -40.6% |
| 2018 | 2.69 Million USD | 14.61% |
| 2017 | 2.35 Million USD | -14.96% |
| 2016 | 2.77 Million USD | -23.4% |
| 2015 | 3.61 Million USD | 39.49% |
| 2014 | 2.59 Million USD | -11.73% |
| 2013 | 2.93 Million USD | -69.68% |
| 2012 | 9.68 Million USD | -23.0% |
| 2011 | 12.58 Million USD | 52.54% |
| 2010 | 8.24 Million USD | -43.66% |
| 2009 | 14.63 Million USD | 95.66% |
| 2008 | 7.48 Million USD | 12.07% |
| 2007 | 6.67 Million USD | -9.71% |
| 2006 | 7.39 Million USD | 4.55% |
| 2005 | 7.07 Million USD | 35.1% |
| 2004 | 5.23 Million USD | 165.84% |
| 2003 | 1.96 Million USD | 168.33% |
| 2002 | 733.85 Thousand USD | 68.14% |
| 2001 | 436.44 Thousand USD | -2.68% |
| 2000 | 448.45 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 253.93 Thousand USD | -23.01% |
| 2024 FY | 986.22 Thousand USD | 14.17% |
| 2024 Q1 | 217.21 Thousand USD | 4.37% |
| 2024 Q2 | 185.24 Thousand USD | -14.72% |
| 2024 Q3 | 329.83 Thousand USD | 78.05% |
| 2023 Q4 | 208.12 Thousand USD | -11.75% |
| 2023 FY | 863.81 Thousand USD | -38.63% |
| 2023 Q3 | 235.84 Thousand USD | 38.67% |
| 2023 Q2 | 170.07 Thousand USD | -31.91% |
| 2023 Q1 | 249.77 Thousand USD | 0.0% |
| 2022 FY | 1.4 Million USD | 36.68% |
| 2021 FY | 1.02 Million USD | -3.24% |
| 2021 Q2 | 321.92 Thousand USD | 46.91% |
| 2021 Q3 | 337.46 Thousand USD | 4.83% |
| 2021 Q1 | 219.12 Thousand USD | -12.46% |
| 2020 Q4 | 250.3 Thousand USD | -4.49% |
| 2020 Q3 | 262.07 Thousand USD | 8.26% |
| 2020 Q2 | 242.07 Thousand USD | -21.9% |
| 2020 Q1 | 309.96 Thousand USD | -23.26% |
| 2020 FY | 1.06 Million USD | -33.63% |
| 2019 Q2 | 345.64 Thousand USD | -20.51% |
| 2019 Q4 | 403.92 Thousand USD | -3.67% |
| 2019 Q3 | 419.32 Thousand USD | 21.32% |
| 2019 FY | 1.6 Million USD | -40.6% |
| 2019 Q1 | 434.84 Thousand USD | -10.29% |
| 2018 Q2 | 678.69 Thousand USD | -14.23% |
| 2018 Q3 | 745.1 Thousand USD | 9.78% |
| 2018 Q4 | 484.71 Thousand USD | -34.95% |
| 2018 Q1 | 791.33 Thousand USD | 47.41% |
| 2018 FY | 2.69 Million USD | 14.61% |
| 2017 FY | 2.35 Million USD | -14.96% |
| 2017 Q2 | 609.96 Thousand USD | -0.97% |
| 2017 Q3 | 592.95 Thousand USD | -2.79% |
| 2017 Q4 | 536.84 Thousand USD | -9.46% |
| 2017 Q1 | 615.94 Thousand USD | 4.74% |
| 2016 FY | 2.77 Million USD | -23.4% |
| 2016 Q1 | 827.38 Thousand USD | -16.03% |
| 2016 Q4 | 588.07 Thousand USD | -11.23% |
| 2016 Q2 | 692.19 Thousand USD | -16.34% |
| 2016 Q3 | 662.43 Thousand USD | -4.3% |
| 2015 Q2 | 853.81 Thousand USD | -8.01% |
| 2015 Q4 | 985.37 Thousand USD | 16.06% |
| 2015 Q3 | 849 Thousand USD | -0.56% |
| 2015 Q1 | 928.16 Thousand USD | 256.18% |
| 2015 FY | 3.61 Million USD | 39.49% |
| 2014 Q2 | 766.85 Thousand USD | 9.67% |
| 2014 Q3 | 865.89 Thousand USD | 12.91% |
| 2014 FY | 2.59 Million USD | -11.73% |
| 2014 Q1 | 699.25 Thousand USD | -48.76% |
| 2014 Q4 | 260.58 Thousand USD | -69.91% |
| 2013 Q3 | 723.95 Thousand USD | 66.8% |
| 2013 FY | 2.93 Million USD | -69.68% |
| 2013 Q4 | 1.36 Million USD | 88.52% |
| 2013 Q2 | 434.02 Thousand USD | 4.7% |
| 2013 Q1 | 414.53 Thousand USD | -67.45% |
| 2012 Q2 | 3.3 Million USD | 10.24% |
| 2012 Q3 | 2.1 Million USD | -36.47% |
| 2012 Q4 | 1.27 Million USD | -39.42% |
| 2012 FY | 9.68 Million USD | -23.0% |
| 2012 Q1 | 3 Million USD | 7.41% |
| 2011 Q3 | 3.24 Million USD | 4.73% |
| 2011 FY | 12.58 Million USD | 52.54% |
| 2011 Q1 | 3.43 Million USD | 38.98% |
| 2011 Q2 | 3.1 Million USD | -9.75% |
| 2011 Q4 | 2.79 Million USD | -13.96% |
| 2010 Q2 | 1.78 Million USD | -17.61% |
| 2010 Q4 | 2.47 Million USD | 34.83% |
| 2010 FY | 8.24 Million USD | -43.66% |
| 2010 Q1 | 2.16 Million USD | -36.27% |
| 2010 Q3 | 1.83 Million USD | 3.02% |
| 2009 Q3 | 4.84 Million USD | 74.76% |
| 2009 FY | 14.63 Million USD | 95.66% |
| 2009 Q4 | 3.39 Million USD | -29.99% |
| 2009 Q1 | 3.63 Million USD | 20.05% |
| 2009 Q2 | 2.77 Million USD | -23.78% |
| 2008 Q3 | 2.13 Million USD | 98.17% |
| 2008 Q1 | 1.24 Million USD | -31.09% |
| 2008 FY | 7.48 Million USD | 12.07% |
| 2008 Q4 | 3.02 Million USD | 41.98% |
| 2008 Q2 | 1.07 Million USD | -13.52% |
| 2007 Q4 | 1.8 Million USD | 55.79% |
| 2007 FY | 6.67 Million USD | -9.71% |
| 2007 Q3 | 1.15 Million USD | -51.99% |
| 2007 Q2 | 2.41 Million USD | 86.4% |
| 2007 Q1 | 1.29 Million USD | -52.22% |
| 2006 Q4 | 2.71 Million USD | 45.0% |
| 2006 FY | 7.39 Million USD | 4.55% |
| 2006 Q1 | 1.37 Million USD | -29.97% |
| 2006 Q2 | 1.43 Million USD | 4.05% |
| 2006 Q3 | 1.87 Million USD | 30.4% |
| 2005 Q3 | 2.01 Million USD | 50.42% |
| 2005 FY | 7.07 Million USD | 35.1% |
| 2005 Q2 | 1.33 Million USD | -23.91% |
| 2005 Q1 | 1.75 Million USD | -9.48% |
| 2005 Q4 | 1.96 Million USD | -2.11% |
| 2004 Q4 | 1.94 Million USD | 7.54% |
| 2004 Q1 | 823.27 Thousand USD | 37.46% |
| 2004 Q2 | 666.17 Thousand USD | -19.08% |
| 2004 FY | 5.23 Million USD | 165.84% |
| 2004 Q3 | 1.8 Million USD | 170.9% |
| 2003 Q1 | 495.6 Thousand USD | 76.13% |
| 2003 FY | 1.96 Million USD | 168.33% |
| 2003 Q4 | 598.9 Thousand USD | 6.53% |
| 2003 Q3 | 562.21 Thousand USD | 79.96% |
| 2003 Q2 | 312.41 Thousand USD | -36.96% |
| 2002 Q4 | 281.38 Thousand USD | 0.38% |
| 2002 FY | 733.85 Thousand USD | 68.14% |
| 2002 Q1 | 21.3 Thousand USD | -61.12% |
| 2002 Q2 | 150.85 Thousand USD | 608.14% |
| 2002 Q3 | 280.31 Thousand USD | 85.82% |
| 2001 FY | 436.44 Thousand USD | -2.68% |
| 2001 Q2 | 21.4 Thousand USD | -89.3% |
| 2001 Q3 | 139.34 Thousand USD | 550.98% |
| 2001 Q4 | 54.78 Thousand USD | -60.69% |
| 2001 Q1 | 200.05 Thousand USD | 0.0% |
| 2000 FY | 448.45 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Medical Technologies Inc. | 3.19 Million USD | 69.098% |
| Ansell Limited | 1.61 Billion USD | 99.939% |
| Ansell Limited | 1.61 Billion USD | 99.939% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 184.64 Million USD | 99.466% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 135.05 Thousand USD | -630.236% |
| Psykey, Inc. | 419.29 Thousand USD | -135.207% |
| ConvaTec Group Plc | 2.19 Billion USD | 99.955% |
| ConvaTec Group Plc | 2.14 Billion USD | 99.954% |
| Encision Inc. | 6.58 Million USD | 85.025% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 1.82 Million USD | 45.958% |
| LifePoint, Inc. | -18.5 Thousand USD | 5430.919% |
| Medite Cancer Diagnostics, Inc. | 6.81 Million USD | 85.524% |
| Paradigm Medical Industries, Inc. | 772 Thousand USD | -27.749% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Reflect Scientific, Inc. | 1.08 Million USD | 8.696% |
| SmileDirectClub, Inc. | 470.74 Million USD | 99.79% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.87 Billion USD | 99.947% |
| SheerVision, Inc. | 3.49 Million USD | 71.818% |
| United Health Products, Inc. | - USD | -Infinity% |
| Vasamed, Inc. | 1.38 Million USD | 28.859% |
| Wearable Health Solutions, Inc. | 745.09 Thousand USD | -32.362% |
| Yubo International Biotech Limited | 104.28 Thousand USD | -845.715% |